Oncothyreon Inc .
 (ONTY)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • May 16, 2013, 12:55 PM

    Oncothyreon (ONTY -20.7%) tanks today after presenting data as ASCO that showed Phase III trials of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 didn't meet its primary objective. The trial was conducted by Merck Serono, a division of Merck (MRK -0.7%), under a license agreement with ONTY.

    | May 16, 2013, 12:55 PM | 3 Comments
  • May 16, 2013, 12:51 PM
    Midday top 10 gainers: EGLE +46%. NBG +24%. SBSA +23%. DQ +22%. GNK +19%. AEGR +19%. GLBS +17%. SINO +17%. PRGN +16%. LWAY +16%.
    Midday top 10 losers: NCT -54%. SNFCA -22%. ONTY -21%. INFI -19%. CNIT -15%. CYCC -14%. PTSX -14%. AMD -13%. BDCO -11%. TRIT -11%.
    | May 16, 2013, 12:51 PM | 2 Comments
  • May 9, 2013, 5:54 PM
    After-hours top gainers, as of 5:30 p.m.: UBNT +10%. UNIS +10%. MCP +7%. WIFI +7%. DAR +6%.
    After-hours top losers: ONTY -10%. AL -8%. AIRM -7%. SNTS -6%. TSEM -6%.
    | May 9, 2013, 5:54 PM
  • Mar. 15, 2013, 3:08 PM

    Oncothyreon (ONTY +0.9%) moves up today on a better than expected Q4 report yesterday, largely shrugging off Cantor Fitzgerald's slashing of its price target to $4.00 from $11.00. The cut relates to ONTY's loss of Stimuvax. Cantor says that despite partner Merck's (MRK) assertion that treatment effects were observed in sub-populations, its financial model assumes that commercialization does not occur and no value is included in its valuation.

    | Mar. 15, 2013, 3:08 PM
  • Mar. 14, 2013, 8:17 AM
    Oncothyreon (ONTY): Q4 EPS of -$0.12 beats by $0.02. (PR)
    | Mar. 14, 2013, 8:17 AM
  • Jan. 2, 2013, 9:10 AM
    Premarket gainers: ZIP +47.94%. POL +18.71%. SGYP +16.92%. MCP +9%. JRCC +8.41%. PAL +7.69%. KWK +7.69%. ZGNX +7.52%. PPHM +6.82%. ONTY +6.77%.
    Losers: ABT -50%.
    | Jan. 2, 2013, 9:10 AM | 6 Comments
  • Dec. 19, 2012, 12:45 PM
    Midday top 10 gainers: AMPL +119%. DYNT +64%. EDAP +25%. ALTE +24%. STP +16%. PTNR +13%. LDK +12%. GBR +19%. CSUN +12%. ELTK +12%.
    Midday top 10 Losers: ONTY -54%. CMGE -21%. PLXT -18%. NICK -15%. DLB -12%. PNTR -11%. PSDV -10%. EGLE -10%. CCUR -10%. PTEK -10%.
    | Dec. 19, 2012, 12:45 PM
  • Dec. 19, 2012, 9:10 AM
    Premarket gainers: PTNR +11%. GM +9%. KCG +8%. RMCF +6%. NBG +6%. VRNG +6%. MLNX +5%
    Losers: ONTY -61%. PLXT -18%. NAV -6%. CYS -6%.
    | Dec. 19, 2012, 9:10 AM | 3 Comments
  • Dec. 19, 2012, 8:39 AM

    Stimuvax, a lung cancer vaccine that Germany's Merck (MKGAF.PK) has licensed from Oncothyreon (ONTY), failed to improve overall survival in a Phase III study. However, "notable treatment effects were observed in certain subgroups of patients." That's not enough to convince analysts: "Despite potential positive effects in subgroups, we consider the drug dead," says Deutsche Bank. Oncothyreon collapses 61%, while Merck is -2.9% in Frankfurt. (PR)

    | Dec. 19, 2012, 8:39 AM
  • Nov. 7, 2012, 4:53 PM
    Oncothyreon (ONTY): Q3 EPS of -$0.15 in-line. (PR)
    | Nov. 7, 2012, 4:53 PM
  • Nov. 7, 2012, 12:10 AM

    Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM

    | Nov. 7, 2012, 12:10 AM
  • Nov. 6, 2012, 5:35 PM

    Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM

    | Nov. 6, 2012, 5:35 PM
  • Aug. 24, 2012, 10:38 AM

    Oncothyreon (ONTY +10.8%) pops after Stifel Nicolaus initiated coverage this morning with a Buy. Not much detail is given, but a couple of catalysts are worth noting. First, its lead product candidate, Stimuvax, is a cancer vaccine in the latter stages of being evaluated in two Phase 3 clinical trials for the treatment of non-small cell lung cancer, with the results due out in early 2013. Second, the shares have lost nearly half their market value since early March, and with the stock currently trading off its 50-day moving average as support, it could be spring-loaded for an upside surprise.

    | Aug. 24, 2012, 10:38 AM
  • Aug. 24, 2012, 9:10 AM
    Premarket gainers: ARUN +14%. MTSL +12%. CPRX +10%. LLY +8%. DSCO +7%. FRO +5%. ONTY +5%.
    Losers: ADSK -22%. HMSY -5%.
    | Aug. 24, 2012, 9:10 AM
  • Aug. 8, 2012, 12:10 AM
    Notable earnings after Wednesday’s close: ATPG, AUY, AVNR, CJES, CLR, CPE, CPNO, CTL, EGLE, EXXI, FTK, GMXR, GSS, GXP, HNSN, HOGS, KGC, MBI, MDRX, MM, MNST, NQ, NWSA, ONTY, PANL, SATC, SCLN, SGEN, SPWR, TEG, ZGNX
    | Aug. 8, 2012, 12:10 AM
  • Aug. 7, 2012, 5:35 PM
    Notable earnings after Wednesday’s close: ATPG, AUY, AVNR, CJES, CLR, CPE, CPNO, CTL, EGLE, EXXI, FTK, GMXR, GSS, GXP, HNSN, HOGS, KGC, MBI, MDRX, MM, MNST, NQ, NWSA, ONTY, PANL, SATC, SCLN, SGEN, SPWR, TEG, ZGNX
    | Aug. 7, 2012, 5:35 PM | 2 Comments
Company Description
Oncothyreon Inc is a clinical-stage biopharmaceutical company. It develops and commercialize synthetic vaccines & small molecules that treat the lives & outcomes of cancer patients.
Sector: Healthcare
Industry: Biotechnology
Country: United States